

# AstraZeneca Development Pipeline

## 28 July 2011

### Line Extensions

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing			
				US	EU	Japan	Emerging
<b>Cardiovascular</b>							
<i>Axanum</i>	proton pump inhibitor + low dose aspirin FDC	low dose aspirin associated peptic ulcer	III	Withdrawn	Filed	2014	Filed
<i>Brilinta</i> PEGASUS-TIMI	ADP receptor antagonist	outcomes study	III	2014	2014	2014	2014
<i>Crestor</i>	statin	outcomes in subjects with elevated CRP	III	Launched	Launched	NA	Filed
Dapagliflozin/ metformin FDC <sup>#</sup>	SGLT2 inhibitor + metformin FDC	diabetes	III	2H 2012	2H 2012		
Kombiglyze XR/ Onglyza/ metformin IR FDC <sup>#</sup>	DPP-4 inhibitor + metformin FDC	diabetes	III	Launched	Filed		Filed
Onglyza SAVOR-TIMI <sup>#</sup>	DPP-4 inhibitor	outcomes study	III	2016			
<b>Gastrointestinal</b>							
<i>Nexium</i>	proton pump inhibitor	peptic ulcer bleeding	III	Filed**	Launched		Launched
<i>Nexium</i>	proton pump inhibitor	GERD	III	Launched	Launched	Approved	Launched
<b>Neuroscience</b>							
<i>Diprivan</i> <sup>#</sup>	sedative and anaesthetic	conscious sedation	III		Launched	2H 2012	Launched
<i>EMLA</i> <sup>#</sup>	local anaesthetic	topical anaesthesia	III		Launched	Filed	Launched
<b>Oncology</b>							
<i>Faslodex</i>	oestrogen receptor antagonist	high dose (500mg) 2 <sup>nd</sup> line advanced breast cancer	III	Launched	Launched	Filed	Launched
<i>Faslodex</i>	oestrogen receptor antagonist	1 <sup>st</sup> line advanced breast cancer	III	2016	2016	2016	2016
<i>Iressa</i>	EGFR tyrosine kinase inhibitor	1 <sup>st</sup> line EGFR mut+ NSCLC	III		Launched	Filed	Launched
<i>Iressa</i>	EGFR tyrosine kinase inhibitor	treatment beyond progression	III		2015	2015	2015
<b>Infection</b>							
<i>FluMist/Fluenz</i>	live, attenuated, intranasal influenza virus vaccine	influenza	III	Launched	Approved		Launched
<b>Respiratory &amp; Inflammation</b>							
<i>Oxis</i>	long-acting $\beta_2$ agonist	COPD	III		Launched	3Q 2011	
<i>Symbicort</i>	inhaled steroid/ long-acting $\beta_2$ agonist	COPD	III	Launched	Launched	4Q 2011	Launched
<i>Symbicort</i>	inhaled steroid/ long-acting $\beta_2$ agonist	SMART	III		Launched	3Q 2011	Launched

<sup>#</sup>Partnered product

\*Kombiglyze XR US; Onglyza/metformin IR FDC EU

\*\* (2<sup>nd</sup>) CRL Received

**NCEs**  
**Phase III/Registration**

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing			
				US	EU	Japan	Emerging
<b>Cardiovascular</b>							
<i>Brilinta/Brilique</i>	ADP receptor antagonist	arterial thrombosis	III	Approved	Launched	2013	Launched
Dapagliflozin <sup>#</sup>	SGLT2 inhibitor	diabetes	III	Filed	Filed	2013	Filed
<b>Neuroscience</b>							
<i>Vimovo</i> <sup>#</sup>	naproxen + esomeprazole	signs and symptoms of OA, RA and AS	III	Launched	Launched		Launched
TC-5214 <sup>#</sup>	neuronal nicotinic channel modulator	major depressive disorder (adjunct)	III	2H 2012	2015		
NKTR-118 <sup>#</sup>	oral peripherally-acting opioid antagonist	opioid-induced constipation	III	2013	2013		
<b>Oncology</b>							
<i>Caprelsa</i> (vandetanib)	VEGFR/EGFR tyrosine kinase inhibitor with RET kinase activity	medullary thyroid cancer	III	Launched	Filed	1H 2012	3Q 2011
<b>Infection</b>							
MEDI-3250 <sup>*</sup>	live, attenuated, intranasal influenza virus vaccine (quadrivalent)	seasonal influenza	III	Filed	TBD		
<i>Zinforo</i> <sup>#</sup> (ceftaroline)	extended spectrum cephalosporin with affinity to penicillin-binding proteins	pneumonia/skin infections	III		Filed		3Q 2011
<b>Respiratory &amp; Inflammation</b>							
Fostamatinib <sup>#</sup>	spleen tyrosine kinase (SYK) inhibitor	rheumatoid arthritis	III	2013	2013		2013

<sup>#</sup>Partnered product

<sup>\*</sup>sBLA in US, MAA in EU

**NCEs**  
**Phases I and II**

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing			
				US	EU	Japan	Emerging
<b>Cardiovascular</b>							
AZD2820	melanocortin receptor type 4 (MC4r) partial agonist peptide	obesity	I				
AZD2927	ion channel blocker/inhibitor	atrial fibrillation	I				
AZD4017	11BHSB inhibitor	glaucoma	I				
AZD7687	diacylglycerol acyl transferase -1 inhibitor	diabetes	I				
AZD8329	11BHSB inhibitor	diabetes	I				
CAT-354	anti-IL-13 MAb	ulcerative colitis	I				
MEDI-2338	anti-IL-18 MAb	post ACS	I				
<b>Neuroscience</b>							
AZD2066	metabotropic glutamate receptor 5 antagonist	chronic neuropathic pain	II				
AZD2423	CCR2b antagonist	chronic neuropathic pain	II				
AZD3480 <sup>#</sup>	alpha4/beta2 neuronal nicotinic receptor agonist	Alzheimer's disease	II				
AZD6765	NMDA receptor antagonist	major depressive disorder	II	2016	2016		
TC-5214 <sup>#</sup>	neuronal nicotinic channel modulator	major depressive disorder (monotherapy)	II				
AZD1446 <sup>#</sup>	alpha4/beta2 neuronal nicotinic receptor agonist	Alzheimer's disease	I				
AZD3241	myeloperoxidase (MPO) inhibitor	Parkinson's disease	I				
AZD3839 <sup>#</sup>	beta-secretase (BACE) inhibitor	Alzheimer's disease	I				
AZD5213	H3AN	Alzheimer's disease/ADHD	I				
MEDI-578	anti-NGF MAb	OA pain	I				

<sup>#</sup>Partnered product

**NCEs**  
***Phases I and II (continued)***

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing			
				US	EU	Japan	Emerging
<b>Oncology</b>							
AZD1152	Aurora kinase inhibitor	haematological malignancies	II				
AZD8931	erbB kinase inhibitor	breast cancer chemo combi/solid tumours	II	2015	2015		
MEDI-575 <sup>#</sup>	anti-PDGFR-alpha mAb	solid tumours	II				
Olaparib	PARP inhibitor	serous ovarian cancer	II	2015	2015	2015	2015
Selumetinib <sup>#</sup> (AZD6244) (ARRY-142886)	MEK inhibitor	solid tumours	II	2015	2015		
AZD1480	JAK1, 2 inhibitor	solid tumours with options in myeloproliferative diseases	I				
AZD2014	TOR kinase inhibitor	solid tumours	I				
AZD3514	androgen receptor downregulator	prostate cancer	I				
AZD4547	FGFR tyrosine kinase inhibitor	solid tumours	I				
AZD5363	AKT inhibitor	solid tumours	I				
AZD8330 <sup>#</sup> (ARRY 424704)	MEK inhibitor	solid tumours	I				
Selumetinib (AZD6244) (ARRY-142886) /MK2206 <sup>#</sup>	MEK/AKT inhibitor	solid tumours	I				
CAT-8015	anti-CD22 recombinant immunotoxin	haematological malignancies	I				
MEDI-551	anti-CD19 MAb	haematological malignancies	I				
MEDI-565	anti-CEA BiTE	solid tumours	I				
MEDI-573 <sup>#</sup>	anti-IGF MAb	solid tumours	I				
MEDI-3617 <sup>#</sup>	anti-ANG-2 MAb	solid tumours	I				
<b>Infection</b>							
AZD9773 <sup>#</sup>	anti-TNF-alpha polyclonal antibody	severe sepsis	II	2015	2015	2015	2015
CAZ104 <sup>#</sup>	beta lactamase inhibitor/ cephalosporin	serious infections	II	NA	2014	2014	2014
CXL104 <sup>#</sup> (CEF104)	beta lactamase inhibitor/ cephalosporin	MRSA	II	NA	2015		2015
AZD5099	Gyrase B	serious infections	I				
AZD5847	oxazolidinone antibacterial inhibitor	tuberculosis	I				
MEDI-534	RSV/PIV-3 vaccine	RSV/PIV prophylaxis	I				
MEDI-550	pandemic influenza virus vaccine	pandemic influenza prophylaxis	I				
MEDI-557	RSV MAb – extended half-life	RSV prevention in high-risk adults (COPD/CHF/ Other)	I				
MEDI-559	RSV vaccine	RSV prophylaxis	I				

<sup>#</sup>Partnered product

**NCEs**  
**Phases I and II (continued)**

Compound	Mechanism	Area Under Investigation	Phase	Estimated Filing			
				US	EU	Japan	Emerging
<b>Respiratory &amp; Inflammation</b>							
AZD1981	CRTh2 receptor antagonist	asthma/COPD	II				
AZD2423	CCR2b antagonist	COPD	II				
AZD3199	iLABA	asthma/COPD	II				
AZD5069	CXCR2	COPD	II				
AZD5423	inhaled SEGRA	COPD	II				
AZD8848	Toll like receptor 7 agonist	asthma	II				
CAM-3001 <sup>#</sup>	anti-GM-CSFR MAb	rheumatoid arthritis	II				
CAT-354	anti-IL-13 MAb	asthma	II				
MEDI-528 <sup>#</sup>	anti-IL-9 MAb	asthma	II				
MEDI-545 <sup>#</sup>	anti-IFN-alpha MAb	SLE	II				
MEDI-563 <sup>#</sup>	anti-IL-5R MAb	asthma	II				
AZD2115	MABA	COPD	I				
AZD8683	muscarinic antagonist	COPD	I				
MEDI-546 <sup>#</sup>	anti-IFN-alphaR MAb	scleroderma	I				
MEDI-551	anti-CD19 MAb	scleroderma	I				
MEDI-570 <sup>#</sup>	anti-ICOS MAb	SLE	I				
MEDI-2338	anti-IL-18 MAb	COPD	I				
MEDI-8968 <sup>#</sup>	anti-IL-1R	COPD	I				

<sup>#</sup>Partnered product

## Development Pipeline - Discontinued Projects vs 27 January 2011

### Cardiovascular/Gastrointestinal

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD1656	diabetes
NCE	AZD5658	diabetes
NCE	AZD6714	diabetes

### Neuroscience

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD2066	major depressive disorder
NCE	AZD3043	short acting sedative/anaesthetic
NCE	TC-5619	cognitive disorders in schizophrenia

### Oncology

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD2461	solid tumours
NCE	AZD7762	solid tumours
NCE	AZD8055	range of tumours
NCE	RECENTIN	NSCLC
NCE	Zibotentan	castrate resistant prostate cancer

### Infection

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD9742	MRSA
NCE	Motavizumab	early and late treatment of RSV in paeds >1 yr

### Respiratory & Inflammation

NCE/Line Extension	Compound	Area Under Investigation
NCE	AZD9819	COPD

### Comments

As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Compounds in development are displayed by phase.